title: T Cell-Associated Immunotherapy for Hepatocellular Carcinoma.
abstract: Hepatocellular carcinoma (HCC) is one of the most common malignant diseases worldwide with limited therapeutic options. Accumulating evidences suggest that immunotherapy could be a promising option for treating HCC. T cell-associated immunotherapy lights up the hope for the improvement of complementary approach to conventional HCC treatments, which needs further research to consummate the clinical consequences. The present work reviewed several T cells associated cellular immunotherapies for HCC, including immune checkpoint blockade, gene-engineered T cells, bispecific T cell engagers, and so on. We also analyzed how these immunotherapies can mediate tumor cell eradication and evaluated their superiority or insufficiency.
authors.forename: Weijie
authors.initials: W
authors.lastname: Ma
authors.forename: Long
authors.initials: L
authors.lastname: Wu
authors.forename: Fuling
authors.initials: F
authors.lastname: Zhou
authors.forename: Zhenfei
authors.initials: Z
authors.lastname: Hong
authors.forename: Yufeng
authors.initials: Y
authors.lastname: Yuan
authors.forename: Zhisu
authors.initials: Z
authors.lastname: Liu
mesh_terms: D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D015979:Killer Cells, Lymphokine-Activated / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D008113:Liver Neoplasms / Q000473:pathology / Q000628:therapy*; D011946:Receptors, Antigen / Q000235:genetics / Q000378:metabolism; D011948:Receptors, Antigen, T-Cell / Q000235:genetics / Q000378:metabolism; D057127:Single-Chain Antibodies / Q000235:genetics / Q000378:metabolism; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology* / Q000378:metabolism; D013602:T-Lymphocytes, Cytotoxic / Q000166:cytology / Q000276:immunology / Q000378:metabolism
chemical_list: D011946:Receptors, Antigen; D011948:Receptors, Antigen, T-Cell; D057127:Single-Chain Antibodies
keywords: Bispecific T cell engagers; Chimeric antigen receptor–engineered T cells; Hepatocellular carcinoma; Immune checkpoint blockade; T cell receptor-engineered T cells; T cellular immunotherapies